Fokkens W J, Backer V, Lund V J, Barnes P J, Bernal-Sprekelsen M, Bjermer L, de Corso E, Conti D M, Cornet M E, Diamant Z, Djukanovic R, Gaga M, Gevaert P, Han J K, Hopkins C, Joos G, Landis B N, Lau S, Lee S E, Mullol J, Peters A T, Scadding G K, Schneider S, Senior B, Pavord I D, Quirce S, Ryan D, Wechsler M E, Hellings P W
Amsterdam UMC, University of Amsterdam, Department of Otorhinolarynogology, Amsterdam, the Netherlands.
Department of Otorhinolaryngology, Head and Neck surgery and Audiology, Rigshospitalet, Copenhagen University Hospitalet, Copenhagen, Denmark.
Rhinology. 2025 Apr 1;63(2):242-244. doi: 10.4193/Rhin24.510.
The introduction of biologics for the treatment of severe upper and lower (type 2) airway inflammation has been a game changer in the management of these diseases. Biologics are injectable medications targeting different molecules relevant in (type 2) inflammation in patients with severe (type 2) airway diseases, like asthma, eosinophilic chronic obstructive pulmonary disease (COPD), chronic rhinosinusitis (CRS) and those who remain uncontrolled despite regular treatment. After the phase 3 trials, showing significant impact on symptoms, quality of life and interventions like surgery (for the upper airways) and exacerbations needing hospitalisation (for the lower airways), biologics are now used in daily practice in many parts of the world. This pocket guide is aimed at all specialists treating adult patients with severe airway disease.
用于治疗严重上、下呼吸道(2型)炎症的生物制剂的引入,在这些疾病的管理方面带来了重大变革。生物制剂是针对患有严重(2型)气道疾病(如哮喘、嗜酸性粒细胞性慢性阻塞性肺疾病(COPD)、慢性鼻-鼻窦炎(CRS))以及那些尽管接受常规治疗仍未得到控制的患者中与(2型)炎症相关的不同分子的注射用药物。在3期试验显示出对症状、生活质量以及诸如手术(针对上呼吸道)和需要住院治疗的病情加重(针对下呼吸道)等干预措施有显著影响之后,生物制剂如今已在世界许多地区的日常临床实践中得到应用。本袖珍指南面向所有治疗成年严重气道疾病患者的专科医生。